Düsing, R
Waeber, B
Destro, M
Santos Maia, C
Brunel, P
Article History
Received: 17 July 2016
Revised: 27 September 2016
Accepted: 20 October 2016
First Online: 23 February 2017
Competing interests
: RD has received honoraria for scientific lectures and financial support for conducting clinical studies from Novartis, Servier, Berlin Chemie and UCB Pharma. MD has received consulting and lecture fees and research grants from Boehringer Ingelheim, AstraZeneca, Servier, Menarini IFR, Schering-Plough, Guidotti, Pfizer, Knoll, Bayer, Chiesi, Daiichi-Sankyo, Merck Sharpe & Dohme and Malesci. MD has also received research support as a study investigator from Novartis Pharma AG and has been a speaker at scientific meetings organised by Novartis. BW has received consulting and lecture fees from Novartis, Pfizer, Menarini and Servier. PB is an employee of Novartis Pharma are thus eligible for Novartis stocks and stock options. CSM was an employee of Novartis at the time of manuscript preparation.